The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma

Chuma, Makoto; Hige, Shuhei; Kamiyama, Toshiya et al.

Journal of Gastroenterology, 2009, 44(9), 991-999

Permalink : https://hdl.handle.net/2115/39478

このアイテムのアクセス数:1,627件（2026-08-24 16:39 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
JG44-9_p991-999 pdf 369 KB 2,470

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/39478
タイトル
The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma
著者
Chuma, Makoto ; Hige, Shuhei ; Kamiyama, Toshiya ; Meguro, Takashi ; Nagasaka, Atsushi ; Nakanishi, Kazuaki ; Yamamoto, Yoshiya ; Nakanishi, Mitsuru ; Kohara, Toshihisa ; Sho, Takuya ; Yamamoto, Keiko ; Horimoto, Hiromasa ; Kobayashi, Tomoe ; Yokoo, Hideki ; Matsushita, Michiaki ; Todo, Satoru ; Asaka, Masahiro
e-Rad_Researcher
30360910
著者名
Chuma, Makoto
e-Rad_Researcher
70261295
著者名
Hige, Shuhei
著者名
Kamiyama, Toshiya
著者名
Meguro, Takashi
著者名
Nagasaka, Atsushi
著者名
Nakanishi, Kazuaki
著者名
Yamamoto, Yoshiya
著者名
Nakanishi, Mitsuru
著者名
Kohara, Toshihisa
著者名
Sho, Takuya
著者名
Yamamoto, Keiko
著者名
Horimoto, Hiromasa
著者名
Kobayashi, Tomoe
著者名
Yokoo, Hideki
e-Rad_Researcher
20250425
著者名
Matsushita, Michiaki
著者名
Todo, Satoru
著者名
Asaka, Masahiro
言語
英語
キーワード
Hepatocellular carcinoma
Hepatitis B virus
Recurrence
Antiviral therapy
発行日
2009-09
出版者
Springer Japan
収録物名
Journal of Gastroenterology
巻(号)
44(9)
ページ
991-999
抄録
Background. Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. Methods. This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log10 copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (≤4 log10 copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Results. Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR, 2.67; 95% CI, 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR, 2.57; 95% CI, 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. Conclusion. HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
The original publication is available at www.springerlink.com
PISSN
0944-1174
関連情報
PMID
19554391
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1007/s00535-009-0093-z